The Future of Neoantigen Discovery: Trends and Challenges

In 2024, the primary trend in oncology is the move toward “true” neoantigens—mutations that
are entirely unique to the patient’s tumor. However, these are often expressed at extremely low
levels.
The challenge is sensitivity. Standard immunopeptidomics often misses these rare signals.
Alithea Bio’s NeoZOOM technology is a specialized solution designed to “zoom in” on these
low-abundance neoantigens. By increasing the dynamic range of detection, NeoZOOM ensures
that even the rarest, most potent neoantigens are identified for use in personalized cancer
vaccines and TCR-T therapies.